DURHAM, NC / ACCESSWIRE / March 5, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing "off-the-shelf" T-cell therapies designed to activate a patient's immune system against cancer, today announced that John Prendergast, Heat Biologic's Lead Board member, will chair a roundtable discussion at 4:00-5:00 pm China Standard Time (CST), on Wednesday, March 6, 2019 at the WuXi Healthcare Forum at the St. Regis Shanghai Jingan Hotel. The Forum brings together more than 5,000 industry leaders from 2,000 organizations spanning 20 countries to share their collective insights on the global challenges facing healthcare and future possibilities.
Dr. Prendergast will chair a panel on oncology, which will focus on promising new developments in the space.
Quelle: ir.heatbio.com/press-releases/detail/625/...cology-roundtable
Dr. Prendergast will chair a panel on oncology, which will focus on promising new developments in the space.
Quelle: ir.heatbio.com/press-releases/detail/625/...cology-roundtable